4/10
01:03 pm
mbx
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $38.00 price target on the stock.
Low
Report
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $38.00 price target on the stock.
4/10
11:20 am
mbx
MBX Biosciences, Inc. (NYSE: MBX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $44.00 price target on the stock.
Low
Report
MBX Biosciences, Inc. (NYSE: MBX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $44.00 price target on the stock.
4/10
10:45 am
mbx
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $38.00 price target on the stock.
Low
Report
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $38.00 price target on the stock.
4/7
08:12 am
mbx
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
Medium
Report
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
4/7
08:00 am
mbx
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
Medium
Report
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
3/26
08:00 am
mbx
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Low
Report
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
3/5
09:56 am
mbx
MBX Biosciences Announces Additions to Leadership Team [Yahoo! Finance]
Medium
Report
MBX Biosciences Announces Additions to Leadership Team [Yahoo! Finance]
3/5
08:00 am
mbx
MBX Biosciences Announces Additions to Leadership Team
Medium
Report
MBX Biosciences Announces Additions to Leadership Team
3/3
08:34 am
mbx
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism [Yahoo! Finance]
Low
Report
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism [Yahoo! Finance]
3/3
08:00 am
mbx
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
Medium
Report
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
2/18
08:07 am
mbx
MBX Biosciences to Participate in March Investor Conferences [Yahoo! Finance]
Low
Report
MBX Biosciences to Participate in March Investor Conferences [Yahoo! Finance]
2/18
08:00 am
mbx
MBX Biosciences to Participate in March Investor Conferences
Low
Report
MBX Biosciences to Participate in March Investor Conferences
1/23
08:00 am
mbx
MBX Biosciences to Participate in Upcoming February Investor Conferences
Medium
Report
MBX Biosciences to Participate in Upcoming February Investor Conferences